Anti-IL-23α (Tildrakizumab), Humanized Antibody

Datasheet
Specifications
Clonality: Monoclonal
Host: Recombinant
Reactivity: Human
Additional Information
Synonyms: MK-3222, SCH 900222, P19, SGRF, IL-23, IL23A, IL23P19
UniProt ID: DB14004

Immunogen

Human IL-23α

Background

The research-grade biosimilar is a humanized IgG1 monoclonal antibody that specifically targets the p19 subunit of IL-23 and thereby inhibits the interaction with the IL-23 receptor. IL-23 is a cytokine that plays an important role in mediating inflammatory and immune responses. Binding of the antibody to Il-23 blocks the release of pro-inflammatory cytokines and chemokines associated with psoriasis. The original drug received approval from the FDA in 2018 to treat patients with moderate-to-severe plaque psoriasis who are candidates for systemic and phototherapy

  • Catalog Number
    A2159-100-BV
  • Supplier
    BioVision
  • Size
  • Shipping
    Blue Ice
  • Price
  • 555,00 €
Add to Cart
you need any help?

Please contact:

Dr. Monika Haas

Tel. +49 (0) 6221 71415 16 info@biocat.com